Items tagged with Drug-resistant TB
Community response to the drug-resistant TB crisis in Europe (post with simple image)
Video summary report from a series of meetings on drug-resistant TB held in May 2017.
TB CAB's proposed development pathway for regimens to treat XDR-TB (post with simple image)
Тhe Global TB Community Advisory Board (TB CAB) releases a position paper regarding the optimal design for future evaluation of regimens for the treatment of extensively drug-resistant TB (XDR-TB).
Advocates call on Indian authorities to ensure immediate access to delamanid (post with simple image)
TB advocates urge the Indian government to develop a concrete plan for introducing delamanid.
People still being denied improved treatment for multidrug-resistant TB (post with simple image)
Médecins Sans Frontières urges governments to step up the use of newer TB drugs.
Tuberculosis: The cornerstone of the AMR threat (post with simple image)
"Tackling TB and drug-resistant TB must be at the heart of any global action against antimicrobial resistance."
Phase III clinical trial results at the 48th Union World Conference on Lung Health: Implications for the field (post with simple image)
Preliminary results from two phase III drug-resistant TB (DR-TB) clinical trials were presented at the 48th Union World Conference on Lung Health: stage 1 of the STREAM trial and the Otsuka 213 delamanid trial.
Support 'My Patient's Choice' pledge (post with simple image)
A carer’s pledge to offer patients an informed choice between a novel drug or an injectable drug for the treatment of MDR-TB.
WHO position statement on the use of delamanid for MDR-TB (post with simple image)
The World Health Organization issues a position statement on the use of delamanid for multidrug-resistant TB following an expedited review of phase III clinical trial results.
Advocates call on WHO to consolidate and revise its guidance regarding the treatment for MDR-TB (post with simple image)
TB CAB issues a position statement on the use of bedaquiline as part of the preferred regimen for MDR-TB.
Giorgia Sulis: Delamanid — a broken dream for patients with MDR-TB? (post with simple image)
When the new TB drug delamanid was approved by the European Medicines Agency (EMA) in 2013, it was one of only two new drugs approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in more than 40 years. Preliminary findings suggested that this new drug could have a promising role for treatment when used with an optimised background regimen (OBR)—results that led to the World Health Organization (WHO) conditionally endorsing the drug in 2014 and providing interim policy guidance.
Page 107 of 117 · Total posts: 0
←First 106 107 108 Last→